Meeting
2023 ASCO Annual Meeting
EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.
Authors
Wolfgang Wick
Universitätsklinikum Heidelberg and German Cancer Research Center, Heidelberg, Germany
Wolfgang Wick , Ahmed Idbaih , Maria Vieito , François Ghiringhelli , Agostina Stradella , Ghazaleh Tabatabai , Michael C. Burger , Iris Mildenberger , Ulrich Herrlinger , Patrick Y. Wen , Mehdi Touat , Antje Wick , Macarena González , Alice Hervieu , Marta Gil-Martin , Mirjam Renovanz , Ana Maia , Christophe Bonny , Jan Fagerberg , David A. Reardon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT04116658
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2020)
DOI
10.1200/JCO.2023.41.16_suppl.2020
Abstract #
2020
Poster Bd #
377
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study.
First Author: Wolfgang Wick
Poster
2022 ASCO Annual Meeting
EO2401, a novel microbiome-derived therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Preliminary results of the SPENCER study.
First Author: Eric Baudin
Poster
2021 ASCO Annual Meeting
Efficacy finding cohort of a cancer peptide vaccine, TAS0313, in treating recurrent glioblastoma.
First Author: Yoshiki Arakawa
Poster
2018 ASCO Annual Meeting
A randomized, multicenter phase 2 study of DSP-7888 dosing emulsion in combination with bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma.
First Author: John Frederick De Groot